Skip to main content
. 2022 Jul 17;15(7):881. doi: 10.3390/ph15070881

Figure 6.

Figure 6

(A,B) In vitro cytotoxicity of blank Lps and blank KLA Lps against (A) human umbilical vein endothelial cells (HUVECs) and (B) MDA-MB-231 cancer cells after treatment for 48 h. (C–E) In vitro cytotoxicity of 5-FU, PTX, 5-FU/PTX, 5-FU/PTX Lps, and KLA-5-FU/PTX Lps against (C) MDA-MB-231, (D) MDA-MB-453, and (E) MDA-MB-436 cancer cells after treatment for 24 h. * p < 0.05, ** p < 0.01, *** p < 0.001. 5-FU, 5-fluorouracil; PTX, paclitaxel; 5-FU/PTX, mechanically mixed free 5-FU and free PTX; 5-FU/PTX Lps, unmodified liposomes co-loaded with 5-FU and PTX; KLA-5-FU/PTX Lps, KLA-modified liposomes co-loaded with 5-FU and PTX.